| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -190.1% | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 1.5 | n/a |
| Pr/Book | 3.6 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 25.0% | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | 0.96 | (1.05) | (12.71)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-21 | 1.15 | (4.14) | (8.05)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | 1.43 | (5.75) | (6.18)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 2.16 | (7.02) | (7.32)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | 2.70 | (5.08) | (2.53)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Notice of Results | 05-Sep-2025 | 07:00 | RNS |
| Trading update | 26-Aug-2025 | 07:00 | RNS |
| De Novo Update – FDA Supervisory Review | 07-Jul-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 1.40p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 6.75 |
| 52 Week Low | 1.39 |
| Volume | 98,711 |
| Shares Issued | 286.88m |
| Market Cap | £4.02m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 10:03 | 5,000 @ 1.50p |
| 09:43 | 71,450 @ 1.39p |
| 09:21 | 67 @ 1.50p |
| 09:21 | 4,505 @ 1.50p |
| 09:00 | 15,000 @ 1.53p |
| CEO | Matthew Heaton Walls |
| CFO | Paul Andrew Peter Foulger |
| COO | Jordi Puig Gilberte |
You are here: research